drugset / Trial / NCT03097939
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma
Phase 2
Active not recruiting
113 enrolled
National Cancer Centre, Singapore
National Taiwan University Hospital · collabNational University of Singapore · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the hypothesis that a combined Immuno-Oncology (IO) strategy would see efficacy in a virally driven cancer like Nasopharyngeal Carcinoma (NPC). Hence, this is a combination study of nivolumab and ipilimumab in Epstein-Barr virus (EBV) driven nasopharyngeal carcinoma.
Timeline
- Start
- 2017-03-31
- Primary completion
- 2027-04-05
- Completion
- 2027-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |